AllergyTalk: The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries - Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma (Non-CME)

The discussion focuses on implementation strategies of an anti-inflammatory reliever in mild asthma patients, with an emphasis on AIR therapy for mild persistent asthma and a comparison of pediatric and adult patients.

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.

Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI; Leonard B. Bacharier, MD, FACAAI

CME is not offered for this podcast.

Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

This podcast miniseries is supported by a grant from AstraZeneca.

Target Audience

Primary Care Physicians
Fellows in Training

Learning Objectives

After listening to this podcast miniseries, participants should be better able to:

  • Expose the prevalence of asthma and exacerbations in the US
  • Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
  • Realize both the genomic and nongenomic mechanisms of action of inhaled asthma therapies
  • Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

You may also be interested in

The Asthma Urgency - Shifting the Rescue Paradigm

This webinar addresses the prevalence of asthma and exacerbations in the US, the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic, the genomic & nongenomic mechanisms of action of inhaled asthma therapies, and the latest exp
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Course opens: 
10/16/2024
Course expires: 
12/31/2025
Rating: 
0

Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose

William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi

Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi

Please login or create an account to take this course.